Dicerna Pharmaceuticals (DRNA) Drops 6.26% on January 12

Equities Staff |

Dicerna Pharmaceuticals (DRNA) was one of the Russell 2000's biggest losers for Tuesday January 12 as the stock slid 6.26% to $7.79, a loss of $-0.52 per share. Starting at an opening price of $8.53 a share, the stock traded between $7.58 and $9.11 over the course of the trading day. Volume was 94,380 shares over 911 trades, against an average daily volume of 146,367 shares and a total float of 20.59 million.

The losses send Dicerna Pharmaceuticals down to a market cap of $160.42 million. In the last year, Dicerna Pharmaceuticals has traded between $27.33 and $7.61, and its 50-day SMA is currently $11.94 and 200-day SMA is $13.79.

Dicerna Pharmaceuticals Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Dicerna Pharmaceuticals is based out of Cambridge, MA and has some 42 employees. Its CEO is Douglas M. Fambrough.

For a complete fundamental analysis analysis of Dicerna Pharmaceuticals, check out Equities.com’s Stock Valuation Analysis report for DRNA. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

CMX Gold & Silver Corp.

CMX Gold & Silver Corp is an exploration stage company. The Company is engaged in the acquisition, exploration and development of silver and copper/gold properties in the USA.

Private Markets

Uber

Uber connects riders with safe, reliable, convenient transportation providers at a variety of price-points in cities around the world. Uber makes money from charging their drivers 20% of the fare…

Ozobot by Evollve Inc

Ozobot is a world leader in compact super intelligent robots that entertain and educate through fun interactive gaming.